AstraZeneca plc vs Tapestry, Inc. — how do they compare? AstraZeneca plc trades at $158.78 (market cap $248.14B), while Tapestry, Inc. trades at $153.42 (market cap $32.44B). The key difference: AstraZeneca plc is far larger — about 7.6× Tapestry, Inc.'s market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | TPR | |
|---|---|---|
Market Cap | $248.14B | $32.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $164.78 |
52-Week Low | $147.06 | $95.69 |
Enterprise Value | $275.41B | $35.29B |
Dividend Yield | 2.01% | 1% |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
TPR trades at $153.17, down 7.05% over 24 hours, with a bullish technical signal from moving averages and strong analyst consensus. The company reported Q1 2026 EPS of $1.66, beating expectations of $1.30, and maintains robust profitability with a gross margin of 76.18% and ROE of 55.74%. Recent news highlights AI integration efforts and upcoming Q4 earnings on August 13, 2026.
Outlook is positive driven by earnings beats and brand momentum, but risks include high valuation multiples and debt levels. The consensus price target is $190.33, implying significant upside, supported by 75.61% buy ratings from analysts. Investors should monitor Q2 2026 earnings and debt management for sustained growth.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →